These suggest that IL-2-enhanced the generation of effector CD8+ T cell response that controlled viral infection in mice, providing a rationale of why Ld-IL2 treatment sustains anti-viral immunity in SLE patients. This evidence concerns the gene CD8A and systemic lupus erythematosus.